Company profile for ImmPACT Bio

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

ImmPACT Bio USA, Inc. is a cell therapy company aiming to develop potent and selective engineered T cells for the treatment of cancer. ImmPACT Bio is developing cutting-edge chimeric antigen receptor (CAR) T-cell technologies to address key biological challenges in treating cancer. ImmPACT-Bio is pioneering a novel strategy to surmount a major challenge compromising current Chimeric Antigen Receptor T-cell (CAR-T) therapy. Our...
ImmPACT Bio USA, Inc. is a cell therapy company aiming to develop potent and selective engineered T cells for the treatment of cancer. ImmPACT Bio is developing cutting-edge chimeric antigen receptor (CAR) T-cell technologies to address key biological challenges in treating cancer. ImmPACT-Bio is pioneering a novel strategy to surmount a major challenge compromising current Chimeric Antigen Receptor T-cell (CAR-T) therapy. Our technology addresses the need to differentiate cancerous from non-cancerous tissues impacting the safety of the treatment which is to date a major limitation in reaching effectiveness.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
4010 Adolfo Rd, Camarillo, California 93012
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

Global ChemShow

Not Confirmed

envelop Contact Supplier

Global ChemShow

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2024/10/31/2972999/0/en/Lyell-Immunopharma-Completes-Acquisition-of-ImmPACT-Bio.html

GLOBENEWSWIRE
31 Oct 2024

https://www.globenewswire.com//news-release/2024/10/24/2969054/0/en/Lyell-Immunopharma-to-Acquire-ImmPACT-Bio-and-Prioritizes-its-Pipeline-to-Focus-on-Next-Generation-CAR-T-cell-Therapies.html

GLOBENEWSWIRE
24 Oct 2024

https://www.prnewswire.com/news-releases/immpact-bio-announces-fda-clearance-of-ind-application-for-cd19cd20-bispecific-car-t-cell-therapy-in-multiple-sclerosis-302226926.html

PR NEWSWIRE
21 Aug 2024

https://www.prnewswire.com/news-releases/immpact-bio-to-present-new-preclinical-data-for-cd19cd20-bispecific-car-t-cell-therapy-in-multiple-sclerosis-302150609.html

PR NEWSWIRE
21 May 2024

https://www.prnewswire.com/news-releases/immpact-bio-to-participate-in-the-2023-truist-securities-biopharma-symposium-301970631.html

PR NEWSWIRE
30 Oct 2023

https://www.prnewswire.com/news-releases/immpact-bio-granted-fda-fast-track-designation-for-impt-314-in-patients-with-relapsed-or-refractory-aggressive-b-cell-lymphoma-301823604.html

PR NEWSWIRE
15 May 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty